[{"orgOrder":0,"company":"SpectraCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpectraCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpectraCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpectraCure \/ Undisclosed"},{"orgOrder":0,"company":"SpectraCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpectraCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpectraCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpectraCure \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Rogers Sciences Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Rogers Sciences Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rogers Sciences Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rogers Sciences Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Modulight, Inc. | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Modulight, Inc. | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Modulight, Inc. | National Cancer Institute"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Jang Won Heo","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Jang Won Heo","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Jang Won Heo"}]

Find Clinical Drug Pipeline Developments & Deals for Verteporfin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 04, 2025

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Roswell Park Cancer Institute

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Roswell Park Cancer Institute

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2024

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Modulight, Inc. | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 01, 2017

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Rogers Sciences Inc.

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Rogers Sciences Inc.

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 20, 2016

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Visudyne is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasm Metastasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 08, 2015

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Central Serous Chorioretinopathy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 29, 2011

                          Lead Product(s) : Verteporfin

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Jang Won Heo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank